Amadeus FiRe AG

  • WKN: 509310
  • ISIN: DE0005093108
  • Land: Deutschland

Nachricht vom 21.10.2021 | 06:57

Amadeus FiRe AG raises earnings forecast again

Amadeus FiRe AG / Key word(s): Change in Forecast/Quarterly / Interim Statement
Amadeus FiRe AG raises earnings forecast again

21-Oct-2021 / 06:57 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Frankfurt/Main, October 21, 2021. Amadeus FiRe AG completed the first nine months of fiscal year 2021 with very positive operations. Significant increases in revenue and earnings were generated in both business segments, Personnel Services and Training. The pre-crisis level has already been clearly exceeded.

Group sales increased by 35.8 percent to EUR 274.8 million and operating profit from operating activities (operating EBITA) by around 75 percent to EUR 49.4 million. Earnings per share, based on the net profit for the period attributable to ordinary shareholders of the parent company, more than doubled to EUR 4.73 in the first nine months of 2021, compared to EUR 2.12 in the previous year.

The positive momentum of the first half-year continued even better than expected in the third quarter. After the Management Board had already significantly raised its earnings forecast at the half-year point to an increase in operating EBITA of at least 50 percent to more than EUR 60 million, the forecast is revised upwards once again. For the full year 2021 the Management Board expects to outperform the earnings threshold of EUR 65 million for operating EBITA.

Amadeus FiRe AG
Jan Hendrik Wessling
Investor Relations
Phone: +49 (69) 96 876-180
Investor-Relations@Amadeus-FiRe.de


21-Oct-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Symrise verlängert Vorstandsvertrag von Dr. Heinz-Jürgen Bertram vorzeitig bis 2025

01. Dezember 2021, 15:38

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

Bio-Gate AG

Original-Research: Bio-Gate AG (von GBC AG): Kaufen

02. Dezember 2021